Trinity Life Sciences Acquires Blueprint Research Group

Waltham, MA, December 8, 2020 — Trinity Life Sciences, the leading commercial partner to the life sciences industry, announced the acquisition of New Jersey-based BluePrint Research Group. The acquisition positions Trinity as the premier partner for commercially focused strategy, insights and analytics for the life sciences industry and solidifies its global presence. BluePrint Research Group adds a London office to Trinity’s international presence as well as increases its current resources in India and the East and West Coasts of the U.S.

The aligned cultures and values of both companies reflect an evidence-first approach to helping clients make critical business decisions.

“We are incredibly excited about the future opportunities that will be realized by way of this partnership – accelerating the comprehensive footprint across insights-driven strategic advisory services that we were prioritizing and envisioning, resulting in considerable professional growth opportunities for our employees and enhanced impact and partnership with our clients,” said Glen Bergstein, Founder and Senior Partner at BluePrint Research Group.

“The life sciences industry is in a period of revolution, where truly breakthrough science is being conducted at a breadth and pace like never before,” said David Fitzhenry, CEO of Trinity. “As partner to the life sciences industry, our purpose is to accelerate the impact of these advancements through deep client partnerships and an evidence-first approach to strategic decision-making. The BluePrint Research Group is a highly regarded player in the life sciences space and shares our commitment to solution-oriented client partnership and a superlative client experience. We will leverage our collective history to enable our clients’ success and ultimately to improve the lives of patients around the globe. We are proud to welcome their first-class team to our organization, and to continue our journey together.”

Trinity and BluePrint clients include the Top 20 pharmaceutical companies* as well as the world’s top life science biotech and medical device companies. The combined entity boasts 500 employees with ten offices across three continents.

BluePrint Research Group Senior Partners, Glen Bergstein, Bala Chandrasekharan and Ryan Fisher, will all stay on with Trinity as Senior Partners.

Madison Park Group acted as exclusive financial advisor to BluePrint Research Group on the transaction.

About BluePrint Research Group

BluePrint was founded in 2008 by three senior professionals with 25 years of combined industry experience in firms such as Bristol Myers Squibb, Schering Plough & Vertex. BluePrint consults with healthcare companies to inform global brand commercialization efforts for the industry’s most innovative therapies and products, impacting and improving global health and wellness. For more information, please visit BluePrintRG.com.

About Trinity Life Sciences

Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.

*Based on the Pharmaceutical Executive Top 50 Global Companies 2019.

To find out more, visit our FAQ section about Trinity’s BluePrint acquisition.